REaCT: REthinking Clinical Trials

REaCT-TNBC

REaCT-TNBC	Optimal chemotherapy for triple negative breast cancer Principal Investigator(s): Dr. John Hilton
ClinicalTrials.gov: NCT02688803
Triple-negative breast cancer (TNBC) is associated with a poorer prognosis than most other types of breast cancer. Despite chemotherapy being the only effective treatment in the curative setting, no one regimen has been identified as being optimal. This study evaluated the feasibility of comparing outcomes for the three most commonly used chemotherapy regimens (Dose dense AC-P vs. FEC-D vs. AC-weekly P) for this disease in an open-label, randomized study. Feasibility was not met in this study and it was closed.
Sites: The Ottawa Hospital
Tags: Early stage Breast Cancer
Publications: Clinical Trial results: Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. Jacobs et al, 2017. PMID: 28127659